Syndax's Q2 Reveals a Shift: From Patient Adds to Duration, and a $2B Peak Sales Claim for Revuforj

Revuforj and Niktimvo both grow double-digits, but the real story is treatment duration elongation and a new frontier in frontline AML.

SNDX · Earnings Call · 2026-08-03

The Quarter at a Glance

Syndax delivered another solid quarter, but the market’s focus has moved beyond simple revenue growth. Net revenue came in at $72.8M – up 92% YoY – with average treatment duration now a central driver. The company explicitly laid out a path to a $2B peak revenue potential for Revuforj in the U.S. alone, underpinned by a deepening post-transplant maintenance adoption. However, the stock sits 20.9% below its July peak, a drawdown that suggests investors are weighing the drop in new patient starts against the duration story. Michael Metzger set the tone: “The business fundamentals are strong. Sales of Revuforj and Niktimvo grew to a combined total of $115 million in the second quarter. Both medicines are now annualizing at well over $200 million each, and we have just started to unlock their multibillion-dollar potential.” — Michael Metzger, Chief Executive Officer · 2026-08-03

Revuforj: Duration Beats New Starts

Revuforj net revenue hit $55M (+12% QoQ) while total prescriptions rose 15%. Yet new patient starts took a step back – the first quarter that happened. Steven Closter repeatedly called it an “anomaly,” citing normal variation and physician choice as menin inhibitors compete. But the company’s real bet is on the transplant maintenance phenomenon: now 50% of post-transplant patients resume therapy, up from 45% last quarter. “We have dominant share of the overall menin business today, having treated over 1,600 patients commercially since launch” — Steven Closter, Chief Commercial Officer · 2026-08-03 – yet the growth engine is the expanding duration, not just new adds. The company also made a bold strategic declaration. In the prepared remarks, Michael said:

With future anticipated indications in frontline AML, we expect that Revuforj could reach in excess of $2 billion in peak annual net revenue in the U.S. alone.
Michael Metzger, Chief Executive Officer · 2026-08-03

This is the first time management formally put a number on the peak, and it uses the longer treatment duration as the key variable. Prior calls show this evolution. In February 2026, Keith had said the restart rate was “40% to 45%” – now it’s 50%. In November 2025, Michael had framed it as “35% to 40%.” The direction is clear, and management now targets 70–80% of transplant patients to return to therapy, with an average duration of 1–2 years.

Niktimvo and the Broader Pipeline

Niktimvo continues to track well, with Q2 net revenue of $60M (+67% YoY) and an annualized run-rate of $240M. The third-line adoption is growing, and the upcoming Phase II IPF and frontline chronic GVHD readouts are the next catalysts. As Steve described, “Nearly every bone marrow transplant center in the U.S. has prescribed Niktimvo and become a repeat customer.” — Steven Closter, Chief Commercial Officer · 2026-08-03 Beyond the commercial assets, Syndax unveiled two new pipeline candidates at its R&D event: SNDX-4321, a mutant-selective allosteric EGFR inhibitor targeting L858R and CNS metastases, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. The later one is particularly notable, building on the company’s leadership in menin inhibition. The company also expects to publish NUP98 relapsed/refractory data in Q4, a subtype they compare to KMT2A in terms of unmet need.

Financial Position and Path to Profitability

Keith Goldan reiterated guidance for ~$400M of R&D+SG&A (excluding non-cash SBC) and highlighted the $575M cash position, including $244M from a June convertible note offering. The company is fully funded through profitability. Total revenue grew 224% YoY to $65M in the latest reported quarter (2026Q1), with Q2 sales even stronger. The conversion to positive operating income remains a story for the future, but the balance sheet is ample. Interestingly, the recent price decline (–19.6% over 90 days) contrasts with the company’s operational momentum. The market appears to be discounting the new patient start dip, while management insists the duration-driven growth is just beginning. The next few quarters, with pivotal data readouts in IPF, frontline GVHD, and frontline AML, will determine if the $2B peak is realistic or hype. In summary, Syndax has crossed a crucial inflection point: expansion opportunity now comes as much from how long patients stay on therapy as from how many new patients are added. The company’s ability to convert that into a sustainable recurring revenue stream will be the key to unlocking the valuation the stock lost in the drawdown.